Biohaven (BHVN) Reports 1st Enrolled Patient in Phase 3 Clinical Trial To Evaluate Rimegepant Zydis ODT
Tweet Send to a Friend
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced today that it has enrolled the first patient in a Phase 3 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
